Venture-capital-backed Vantia Ltd has raised £4 million in a Series B round to support the clinical development of two candidate small molecule drugs for the treatment of dysmenorrhoea and for nocturia. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
